Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed
Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from widespread shortages in the U.
Mounjaro's Sales Likely To Rise 2.5x Driving Eli Lilly's Q3 Performance
The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the consensus estimates.
Eli Lilly’s Q3 Miss for Mounjaro, Zepbound Highlights Dependency on Wholesalers
Lilly CEO Dave Ricks in Wednesday’s third-quarter earnings call acknowledged that the company is at the mercy of wholesaler stocking decisions.
Eli Lilly Stock Plummets As Zepbound, Mounjaro Sales Miss Estimates
Eli Lilly has amassed a market value nearing a trillion dollars based on the assumption that demand for its new weight-loss medicine Zepbound will be virtually bottomless. After the company reported disappointing third-quarter results Wednesday morning,
Eli Lilly’s stock tumbles as Mounjaro, Zepbound sales miss by wide margins
Eli Lilly’s stock heads for biggest selloff since 2008 after sales of anti-obesity drugs Mounjaro and Zepbound came up well short of forecasts.
Lilly Hit With Lower-Than-Expected Mounjaro and Zepbound Q3 Sales, Narrows Full-Year Forecast
Eli Lilly’s blockbuster weight loss and diabetes drugs missed analysts’ expectations by 18% in the third quarter, which were negatively impacted by inventory stocking in the wholesaler channel. The company’s shares fell more than 13% in trading on Wednesday morning.
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still fell short
Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from widespread shortages in the U.
Eli Lilly’s stock tumbles as Mounjaro, Zepbound sales miss expectations by wide margins
Shares of Eli Lilly and Co. tumbled 9.6% in premarket trading Wednesday, after the drug maker reported third-quarter profit and revenue that missed expectations by wide margins, as sales of obesity drugs Mounjaro and Zepbound came up well short of forecasts.
Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...
Ozempic, Wegovy or Mounjaro: the battle of the weight-loss injections
As weight-loss injections emerge as key players in the government’s anti-obesity strategy, Emma Loffhagen goes inside the ...
GP busts six common myths about Ozempic, Mounjaro, Wegovy and weight loss jabs
A staggering 64% of adults in England are classed as either overweight or obese according to the most recent NHS figures. And ...
Becker's Hospital Review12d
FDA retreats from declaring end to Mounjaro shortage
In a reversal, the FDA is reconsidering its decision to end the shortage status of tirzepatide, after a recent lawsuit and intense public pressure, The Washington Post reported Oct. 21.
Eli Lilly Misses Quarterly Profit Estimates; Shares Tumble
(Reuters) -Eli Lilly missed Wall Street estimates for third-quarter profit on Wednesday, hurt by higher manufacturing costs ...
Ibj.com3d
UPDATE: Lilly shares tumble on earnings report that falls short of Wall Street expectations
The Indianapolis-based drugmaker missed expectations on sales of two popular drugs, diabetes treatment Mounjaro and ...